Genetic variant involved in determining C5a complement levels
- Technology Benefits
- • No clinically available tests for risk stratification of complications due to high C5a complement levels are currently available. • Noninvasive method for determining an individual's risk for septic shock after exposure to an infectious agent. • Improvement on already commercially available tests that measure C5a.• Genetic variant can be used to monitor sensitivity to drugs that target C5a.
- Technology Application
- • Early detection of "at risk" populations for elevated C5a levels.• Development of better treatment for diseases associated with high C5a levels, such as septic shock syndrome and renal diseases.• Genetic typing of this variant could be incorporated into commercially available tests.• Development of new standards for C5a ELISA assays.• Measuring the effectiveness of drugs that target C5a
- Detailed Technology Description
- This technology identifies a major genetic regulator of C5a complement levels. In a genome-wide association study, it was found that this particular genetic variant accounts for 36% increase in baseline C5a levels in healthy individuals. The variatio...
- *Abstract
-
None
- *Inquiry
- Jerry KokoshkaColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- CU12058
- *Principal Investigator
-
- Country/Region
- USA
For more information, please click Here
